The Short Answer
For about twenty years, dopamine agonists — pramipexole (Mirapex), ropinirole (Requip), and the rotigotine patch (Neupro) — were the standard first choice for restless legs syndrome (RLS). They worked quickly, they worked well, and they were FDA-approved specifically for RLS.
The 2025 American Academy of Sleep Medicine (AASM) guideline changed that. Dopamine agonists were downgraded from first-line therapy, and alpha-2-delta ligands and iron therapy took their place.
The reason is not that dopamine agonists don't work. It is that with long-term daily use, they too often end up making RLS worse than it was before treatment — a phenomenon called augmentation — and they carry an underappreciated risk of impulse control problems. This article explains both, why it took decades to change course, and what to do if you are taking one now.
How Dopamine Agonists Became First-Line in the First Place
RLS is closely tied to dopamine, the brain chemical that helps regulate movement. Dopamine signaling naturally dips in the evening, which is part of why RLS symptoms follow a daily rhythm and worsen at night. Iron is a required building block for making dopamine, which is why brain iron deficiency sits at the center of the condition.
Given that biology, drugs that stimulate dopamine receptors were a logical fit — and in the short term, they are impressively effective. Many patients feel dramatic relief within days, at doses far lower than those used in Parkinson's disease. Ropinirole became the first FDA-approved RLS medication in 2005, pramipexole followed in 2006, and the rotigotine patch in 2012. Guidelines through the 2000s and early 2010s reasonably placed them first-line, and millions of prescriptions followed.
The problem only became visible with time — years of it.
Augmentation: When the Treatment Becomes the Disease
Augmentation is a gradual, medication-driven worsening of RLS. The drug keeps "working" in the sense that each dose still brings relief — but the underlying condition intensifies underneath it.
What It Looks Like
Augmentation has a recognizable signature that distinguishes it from the natural progression of RLS:
- Symptoms start earlier in the day. What was once an 10 PM problem becomes an evening problem, then an afternoon problem. In severe cases, symptoms are present most of the day.
- Symptoms appear faster at rest. Sitting down to dinner or a movie triggers symptoms within minutes, where it once took an hour.
- Symptoms spread. Sensations that were confined to the legs appear in the arms, and occasionally the trunk.
- Relief gets shorter. Doses wear off sooner, inviting earlier or extra dosing.
- Intensity increases. The urge to move becomes stronger and harder to suppress.
The trap is that each of these changes looks like the disease getting worse — so the intuitive response, for patient and prescriber alike, is to raise the dose. That brings short-term relief and medium-term acceleration: higher doses drive further augmentation. Many patients cycle through several dose increases over years before the pattern is recognized.
How Common Is It?
Common enough to sink the drug class. Roughly 7-8% of patients per year on pramipexole develop augmentation, and the risk compounds with every year of use — long-term studies find rates of 50-70% with extended daily therapy. The rotigotine patch appears somewhat slower to cause augmentation, but it is not exempt. Risk is higher with higher doses, longer duration of use, and — notably — low ferritin, which is one more reason iron status is checked before and during any RLS treatment.
Why It Happens
The leading explanation is that continuous stimulation from the medication causes the dopamine system to adapt against it — receptors become less responsive in some pathways and overactive in others, particularly in the spinal circuits that process sensation and movement. The net effect is a nervous system more sensitized to RLS than before treatment. Low brain iron appears to make this maladaptation easier, tying the augmentation story back to the core biology of the disease.
Why It's Hard to Undo
Escaping augmentation usually means tapering off the dopamine agonist — and the taper itself is rough. Symptoms temporarily rebound, often intensely, for days to weeks. Most patients need a bridge: iron optimization, an alpha-2-delta ligand started in advance, and sometimes, in severe refractory cases, a low-dose opioid under specialist supervision. It is very manageable with a good plan, but it is genuinely unpleasant — which is exactly why the guidelines now aim to prevent patients from reaching this point at all.
The Second Problem: Impulse Control Disorders
Dopamine is central to the brain's reward system, and stimulating it has behavioral consequences that have nothing to do with legs. A meaningful minority of patients taking dopamine agonists — estimates in RLS studies generally range from about 6% to 17% — develop impulse control disorders: compulsive gambling, compulsive shopping, binge eating, or hypersexual behavior that was not present before the medication.
Two things make this side effect particularly insidious:
- Patients rarely connect it to the pill. A new gambling habit does not feel like a drug side effect, and many people are too embarrassed to mention it at a medical visit.
- It can be financially and personally devastating before anyone identifies the cause.
The behaviors typically resolve when the medication is reduced or stopped. If you or a family member notice new compulsive behavior in someone taking pramipexole, ropinirole, or rotigotine — for any condition — raise it with the prescriber promptly. Excessive daytime sleepiness, including sudden "sleep attacks," is another dopamine agonist side effect worth knowing about, particularly for drivers.
What the 2025 Guidelines Actually Say
The 2025 AASM clinical practice guideline formalized the shift that RLS specialists had been making for years:
- Iron evaluation and treatment come first for everyone — ferritin at or below 75 mcg/L (or transferrin saturation under 20%) warrants iron therapy, with a strong recommendation for IV ferric carboxymaltose in appropriate patients.
- Alpha-2-delta ligands — gabapentin, gabapentin enacarbil, and pregabalin — received strong recommendations and are the preferred starting medications. They are comparably effective to dopamine agonists in trials and, critically, do not cause augmentation.
- Dopamine agonists were downgraded to conditional options, reserved for patients in whom alpha-2-delta ligands fail, are not tolerated, or are contraindicated — at the lowest effective dose, with monitoring.
The 2026 RLS Foundation management algorithm published in Mayo Clinic Proceedings takes the same position, and adds practical guidance for the hardest part: safely getting long-treated patients off dopamine agonists.
It is worth being precise about what the guidelines did not say. They did not declare dopamine agonists ineffective or dangerous for every patient, and they did not instruct anyone to stop them abruptly. Intermittent, as-needed dopaminergic use for occasional symptoms remains a reasonable strategy in selected patients, because augmentation risk tracks with continuous daily exposure.
If You Are Taking a Dopamine Agonist Now
This is the question that matters most to the many patients who started one of these medications years ago — often appropriately, under the guidelines of the time.
Do not stop on your own. Abruptly discontinuing a dopamine agonist reliably triggers a rebound of severe symptoms, and after long-term use some patients experience a broader withdrawal syndrome (anxiety, low mood, fatigue). Any change should be planned and supervised.
If you are stable, this is a conversation, not an emergency. A patient doing well on a low, unchanged dose with no signs of augmentation does not need to switch today. The updated guidance is a reason to review the plan at your next visit, weigh the long-term risk, and make sure ferritin is optimized.
If you have augmentation warning signs, act sooner. Earlier symptom onset, spread to the arms, faster onset at rest, or a history of repeated dose increases are reasons to seek a reassessment now — ideally with a sleep specialist. The standard playbook is:
- Check the full iron panel and treat aggressively if ferritin is below target — iron correction alone can make the transition far easier.
- Review for aggravating factors — antihistamines, certain antidepressants, alcohol, and untreated sleep apnea can all amplify symptoms.
- Start an alpha-2-delta ligand and allow it to reach an effective dose.
- Taper the dopamine agonist slowly — typically over weeks to months, expecting a temporary rough patch.
- For severe, refractory cases, specialist options including low-dose opioid therapy exist and are explicitly acknowledged in current guidelines.
Most patients come through this transition with better long-term control than they had on the escalating dopamine agonist — but the process deserves clinical support, not a solo attempt.
The Bigger Lesson
The rise and fall of dopamine agonists in RLS is a case study in why medicine keeps re-examining its own standards. The drugs passed rigorous trials — short ones. The harm emerged on a timescale the trials never measured. It took independent registries, long-term cohorts, and two decades of clinical experience to see the full picture, and the guidelines eventually followed the evidence, as they should.
For patients, the practical summary is simple: iron first, alpha-2-delta ligands when medication is needed, and dopamine agonists as a carefully monitored fallback rather than a default — with a planned, supported exit for those whom the old default no longer serves.
Key Takeaways
- Dopamine agonists (pramipexole, ropinirole, rotigotine) were first-line RLS therapy for ~20 years and work very well short-term
- Augmentation — a medication-driven worsening of RLS — is the core reason they were demoted, affecting 50-70% of long-term users; raising the dose feels like the fix but fuels the problem
- Impulse control disorders (gambling, shopping, hypersexuality) affect roughly 6-17% of RLS patients on these drugs and often go unrecognized as a side effect
- The 2025 AASM guideline now recommends iron evaluation first and alpha-2-delta ligands (gabapentin, gabapentin enacarbil, pregabalin) as the preferred medications — they do not cause augmentation
- Never stop a dopamine agonist abruptly — rebound symptoms can be severe; transitions should be gradual and supervised, ideally after iron is optimized
- Warning signs of augmentation: symptoms earlier in the day, spreading to the arms, faster onset at rest, doses wearing off sooner — bring these to your clinician promptly